CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 9, 2009--
Biogen Idec Inc. (NASDAQ:BIIB) today announced that, based on a
preliminary tabulation by the independent inspector of elections, IVS
Associates, Robert W. Pangia, William D. Young, Alexander J. Denner and
Richard C. Mulligan have been elected to the Company’s Board of
Directors. Their terms take effect upon final certification of the
results of the stockholder vote by IVS Associates.
The Company also announced that the preliminary tabulation by IVS
Associates confirms stockholders voted to institute majority voting in
uncontested elections, ratify the Company’s auditor, and reject
proposals to change the Company’s jurisdiction of incorporation to North
Dakota and set the size of the Board at 13.
Bruce R. Ross, Biogen Idec’s Chairman, said, “We welcome Alexander
Denner and Richard Mulligan to the Board and look forward to working
with them to build on Biogen Idec’s strong track record of delivering
About Biogen Idec
Biogen Idec creates new standards of care in therapeutic areas with high
unmet medical needs. Founded in 1978, Biogen Idec is a global leader in
the discovery, development, manufacturing, and commercialization of
innovative therapies. Patients in more than 90 countries benefit from
Biogen Idec's significant products that address diseases such as
lymphoma, multiple sclerosis, and rheumatoid arthritis. For product
labeling, press releases and additional information about the company,
please visit www.biogenidec.com.
Source: Biogen Idec Inc.
Biogen Idec Media Contact:
Jennifer Neiman, 617-914-6524
Manager, Public Affairs
Biogen Idec Investor Relations
Eric Hoffman, 617-679-2812